{
  "docId": "019de073-742c-704c-a810-4500da4f1d81",
  "docSlug": "e78883ddf681fdb15564423388c7a078",
  "documentTitle": "Allarity Therapeutics | Investor Conference Presentation Deck | 23 slides",
  "authorId": "allarity-therapeutics",
  "authorName": "Allarity Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 23,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_messages",
  "function": "quantify_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a stacked bar chart showing market growth from 2019A to 2026E.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-742c-704c-a810-4500da4f1d81/13",
  "deckHref": "/decks/019de073-742c-704c-a810-4500da4f1d81",
  "deckJsonHref": "/decks/019de073-742c-704c-a810-4500da4f1d81.json",
  "deckAnchorHref": "/decks/019de073-742c-704c-a810-4500da4f1d81#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.62,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Annual sales (US$m) in indications targeted by Stenoparib with DRP",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e43c635-f59d-4309-a674-c0509dec3413",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Exclusively in-licensed from Eisai. First-in-class small molecule targeted inhibitor of DNA damage repair enzymes (PARP) with dual Tankyrase inhibitor activity (Wnt signaling). Stenoparib has shown promising monotherapy activity against OC and pancreatic cancer in prior Phase 1 clinical trial. Validated Stenoparib-DRP® cDx showed ability to identify patients that benefited in Phase I study. Ongoing Phase 2 monotherapy study in OC – started at Dana-Farber Cancer Institute (U.S.). Ongoing opening of new sites in U.S. and EU in 2022 to accelerate enrollment. Global PARP market projected to reach $9 Billion by 2027 for use in ovarian cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9515d978-3f67-4fc9-b4da-a75fffa4aebf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "1. PARP = Poly ADP-Ribose Polymerase... 2. Under Eisai... 3. Plummer et al... 4. NCT03878849",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b42ab85-1d85-4621-99eb-16e4321051ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "Ongoing Phase 2 Monotherapy Study in 2nd Line OC with Anticipated Interim Data Readout Late Q4 2022",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5529bb62-9b2c-4362-b42b-90994d159ec2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Stenoparib: A Dual PARP and Tankyrase Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04884093-8562-48bc-8bb4-b3baee6c6b1c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a2f84711-4fae-4918-b5d6-e5c2011e4e75",
      "evidence": "The slide features a list of bullet points highlighting the characteristics and benefits of Stenoparib, including its dual PARP and Tankyrase inhibitor activity.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b256bbaf-5ead-4fee-9327-1e3695ac93a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents DRP as a solution to the problem, highlighting its potential to personalize cancer care and improve patient outcomes.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}